Ocugen seeks to sell 100 million doses of Bharat Biotech's Covaxin in US in 2021

The Pennsylvania-based biopharmaceutical firm is partnering with India's Bharat Biotech, a developer of the vaccine, to commercialize the shot in the United States. COVAXIN was shown to be 81% effective in an interim analysis of late-stage trial data on some 26,000 people in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3bQRpvS
via IFTTT